The tariff classification of Brazikumab (MEDI2070) and Brazikumab (AMG 139 MEDI2070) (CAS No. 1610353-18-8) in dosage form, from the United States and imported from Ireland
Reasoning
The tariff classification of Brazikumab (MEDI2070) and Brazikumab (AMG 139 MEDI2070) (CAS No. 1610353-18-8) in dosage form, from the United States and imported from Ireland
Cite this ruling
CBP Ruling N301102 (3002150000): The tariff classification of Brazikumab (MEDI2070) and Brazikumab (AMG 139 MEDI2070) (CAS No. 1610353-18-8) in dosage form, from the United States and imported from Ireland
Paste this into a product's override reason when citing this ruling as justification for a classification.
Other rulings for HS6 300215
The tariff classification of HEC88473 Drug Product (also known as APL-18881) in dosage form, from China
The tariff classification of clinical trial kits from the United States
The tariff classification of Hyrimoz® (adalimumab-adaz) Injection in dosage form, from Austria
The tariff classification of various recombinant proteins packed for retail sale from India
The tariff classification of HRP Conjugated antibodies from India